JPH06100468A - Sustained release composition - Google Patents
Sustained release compositionInfo
- Publication number
- JPH06100468A JPH06100468A JP25627392A JP25627392A JPH06100468A JP H06100468 A JPH06100468 A JP H06100468A JP 25627392 A JP25627392 A JP 25627392A JP 25627392 A JP25627392 A JP 25627392A JP H06100468 A JPH06100468 A JP H06100468A
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- release composition
- hyaluronic acid
- release
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、内容物を特定の時間に
わたって所望のパターンで放出することができる徐放性
組成物に関する。本発明の徐放性組成物は、医薬品、食
品、各種材料など幅広い分野において応用しうるもので
ある。FIELD OF THE INVENTION The present invention relates to a sustained release composition capable of releasing a content in a desired pattern over a specific period of time. INDUSTRIAL APPLICABILITY The sustained-release composition of the present invention can be applied in a wide range of fields such as pharmaceuticals, foods and various materials.
【０００２】[0002]
【従来の技術】徐放性組成物は、長時間にわたり内容物
を放出することができるため、放出された内容物がもた
らす特定の効果を長く維持することができる。とくに、
医薬品の分野においては薬効を長時間にわたり持続させ
ることができ、薬物投与回数を減らし継続性のある治療
を行うことができる点で極めて有用である。BACKGROUND OF THE INVENTION Sustained-release compositions can release their contents over a long period of time, so that the specific effect of the released contents can be maintained for a long time. Especially,
In the field of pharmaceuticals, it is extremely useful in that the drug effect can be sustained for a long time, the number of drug administrations can be reduced, and continuous treatment can be performed.
【０００３】しかし、医薬品等として使用するために
は、毒性・刺激性がないことが必要条件であり、その成
分は自ずと限られたものに制限されてしまう。このた
め、医薬品として問題なく使用することができて、しか
も徐放性のすぐれた組成物は数少ない。However, in order to use it as a medicine or the like, it is a necessary condition that it is not toxic or irritating, and its components are naturally limited to limited ones. For this reason, there are few compositions that can be used as pharmaceuticals without problems and have excellent sustained release.
【０００４】このような条件を満たすものとして、各種
天然ポリマー、合成ポリマーを用いたものとともにアル
ギン酸を用いた徐放性組成物が開発されている。その中
には、塩基性薬物をアルギン酸ゲルビーズに包含させた
ものや、種々の乾燥手段によって乾燥したアルギン酸系
徐放性組成物などがある。しかしながら、放出させるべ
き内容物を組成物中に固定化することは必ずしも容易で
はない。また、内容物を固定化できたとしても、内容物
の放出パターンを所望のかたちにできないことが多い。
このために、アルギン酸を含有する徐放性組成物の応用
範囲はおのずと限定されたものとなり、それが該徐放性
組成物の実用性と有用性を狭めていた。As those satisfying such conditions, sustained-release compositions using alginic acid have been developed as well as those using various natural polymers and synthetic polymers. Among them, there are alginic acid gel beads containing a basic drug, alginic acid-based sustained-release compositions dried by various drying means, and the like. However, it is not always easy to immobilize the contents to be released in the composition. Even if the contents can be immobilized, the release pattern of the contents cannot be formed in a desired shape in many cases.
Therefore, the application range of the sustained-release composition containing alginic acid is naturally limited, which narrows the practicality and usefulness of the sustained-release composition.
【０００５】[0005]
【発明が解決しようとする課題】本発明は、薬物などの
内容物を安定に固定化することができて、しかも優れた
徐放性を示す徐放性組成物を提供することを目的とす
る。また、本発明は、内容物の放出パターンを所望のか
たちにすることができる徐放性組成物を提供することを
も目的とする。DISCLOSURE OF THE INVENTION It is an object of the present invention to provide a sustained release composition capable of stably immobilizing contents such as a drug and exhibiting excellent sustained release property. . Another object of the present invention is to provide a sustained-release composition capable of forming the release pattern of the content in a desired shape.
【０００６】[0006]
【課題を解決するための手段】かかる課題は、放出させ
る内容物、アルギン酸およびヒアルロン酸からなる徐放
性組成物を提供する本発明によって解決された。SUMMARY OF THE INVENTION This problem has been solved by the present invention which provides a sustained release composition consisting of a content to be released, alginic acid and hyaluronic acid.
【０００７】本発明の徐放性組成物の成分であるアルギ
ン酸およびヒアルロン酸は、通常使用されるものであれ
ば特に制限なく使用することができる。また、放出され
る内容物は、薬効物質、色素などその種類を問わない。
例えば、鎮痛消炎活性を有するジクロフェナクナトリウ
ムや、抗てんかん活性を有するフェニトインなどを用い
ることができる。Alginic acid and hyaluronic acid, which are components of the sustained-release composition of the present invention, can be used without particular limitation as long as they are commonly used. Further, the content to be released may be any kind such as a medicinal substance and a pigment.
For example, diclofenac sodium having analgesic and anti-inflammatory activity, phenytoin having antiepileptic activity and the like can be used.
【０００８】本発明の徐放性組成物は、放出させる内容
物、アルギン酸およびヒアルロン酸の３つの成分を含有
するものであれば、その他の成分の種類や構造は特に制
限されない。したがって、他の成分として、キトサンな
どを含有させてもよいし、放出させる内容物として複数
の活性物質を添加してもよい。また、本発明の徐放性組
成物は胃溶性の被膜で覆うなどして多層構造にしてもよ
いし、外層にのみさらにキトサンなどを添加した構造に
してもよい。さらに、本発明の徐放性組成物の状態も特
に限定されず、ハイドロゲル状であってもキセロゲル状
であってもよい。The sustained-release composition of the present invention is not particularly limited in the type and structure of the other components as long as it contains the three components of the content to be released, alginic acid and hyaluronic acid. Therefore, as other components, chitosan or the like may be contained, and a plurality of active substances may be added as contents to be released. The sustained-release composition of the present invention may have a multi-layer structure by covering it with a gastric-soluble coating, or may have a structure in which chitosan or the like is further added only to the outer layer. Furthermore, the state of the sustained-release composition of the present invention is not particularly limited, and may be hydrogel or xerogel.
【０００９】本発明の徐放性組成物は、当業者に公知の
方法によって調製することができる。例えば、放出させ
る内容物をヒアルロン酸を含むアルギン酸ナトリウム溶
液に溶解し、カルシウム溶液に滴下後、放置することに
よって徐放性組成物を得ることができる。この方法によ
って、放出させる内容物はほぼ定量的に固定化すること
ができる。The sustained release composition of the present invention can be prepared by methods known to those skilled in the art. For example, the sustained-release composition can be obtained by dissolving the content to be released in a sodium alginate solution containing hyaluronic acid, dropping it in a calcium solution, and leaving it to stand. By this method, the contents to be released can be immobilized almost quantitatively.
【００１０】本発明の徐放性組成物は、必須成分である
ヒアルロン酸の含有量を変えることによってその放出パ
ターンを変化させることができる。例えば、図１および
図２に示すように、ヒアルロン酸の含有量を高くするこ
とによって、より徐放性を強化することができる。ま
た、別の必須成分であるアルギン酸の種類を変えること
によって放出パターンを変化させることもできる（図
３）。さらに、キトサンなどの任意成分を添加すること
によっても放出パターンを変化させることができる。し
たがって、ヒアルロン酸含有量、アルギン酸の種類およ
びキトサン含有量を適宜選択することによって、使用目
的にあった所望の放出パターンを有する徐放性組成物を
調製することができる。このため、本発明の徐放性組成
物の有用性は極めて高いものである。The sustained-release composition of the present invention can change its release pattern by changing the content of hyaluronic acid which is an essential component. For example, as shown in FIGS. 1 and 2, the sustained release property can be further enhanced by increasing the content of hyaluronic acid. The release pattern can also be changed by changing the type of alginic acid, which is another essential component (Fig. 3). Further, the release pattern can be changed by adding an optional component such as chitosan. Therefore, by appropriately selecting the hyaluronic acid content, the type of alginic acid, and the chitosan content, a sustained release composition having a desired release pattern suitable for the intended purpose can be prepared. Therefore, the usefulness of the sustained-release composition of the present invention is extremely high.
【００１１】[0011]
【実施例】以下に実施例を挙げて本発明の徐放性組成物
の調製法について具体的に説明する。これらの実施例で
は、以下の表に示す多糖類を用いた。なお、実施例にお
けるヒアルロン酸・キトサンは、それぞれヒアルロン酸
ナトリウム・キトサングルタミン酸塩として供給した。EXAMPLES The method for preparing the sustained-release composition of the present invention will be specifically described below with reference to the examples. In these examples, the polysaccharides listed in the table below were used. In addition, hyaluronic acid and chitosan in the examples were supplied as sodium hyaluronate and chitosan glutamate, respectively.
【００１２】[0012]
【表１】 使用した多糖類 ヒアルロン酸ナトリウム ＦＣＨ 紀文フードケミファ社製 アルギン酸ナトリウム ＮＳＰＨ２ 紀文フードケミファ社製 アルギン酸ナトリウム ５００Ｇ 紀文フードケミファ社製 アルギン酸ナトリウム ２０Ｍ 紀文フードケミファ社製 キトサングルタミン酸塩 プロノバＢＭＶ プロタン社製 （実施例１）フェニトインを用いた本発明の徐放性組成
物の調製 ヒアルロン酸（０.０５〜２％）とアルギン酸ナトリウ
ム［ＮＳＰＨ２］（１％）を含む水溶液２ｍｌに、フェ
ニトイン１０ｍｇを溶解した。この溶液をノズルを用い
て、塩化カルシウム（０.２Ｍ）とキトサン（０.１％）
を含む０.１Ｍ酢酸緩衝液（ｐＨ４.７）２５ｍｌ中に滴
下した。３７℃で４８時間放置した後、脱イオン蒸留水
５０ｍｌで１回洗浄して、本発明の徐放性組成物を得
た。[Table 1] Polysaccharides used Sodium hyaluronate FCH Sodium alginate manufactured by Kibun Food Chemifa NSPH2 Sodium alginate manufactured by Kibun Food Chemifa 500G Sodium alginate manufactured by Kibun Food Chemifa 20M Chitosan glutamate manufactured by Kibun Food Chemifa Pronova BMV Protan ( Example 1) Preparation of sustained-release composition of the present invention using phenytoin 10 mg of phenytoin was dissolved in 2 ml of an aqueous solution containing hyaluronic acid (0.05 to 2%) and sodium alginate [NSPH2] (1%). Using a nozzle, this solution was added with calcium chloride (0.2M) and chitosan (0.1%).
Was added dropwise to 25 ml of a 0.1 M acetate buffer (pH 4.7) containing. After leaving it at 37 ° C. for 48 hours, it was washed once with 50 ml of deionized distilled water to obtain a sustained release composition of the present invention.
【００１３】また、キトサンを含まない酢酸緩衝液を用
いて同様の操作を行って、別の本発明の徐放性組成物を
得た。さらに、ヒアルロン酸を用いないで同様の操作を
行って、対照用徐放性組成物を得た。Further, the same operation was carried out using an acetate buffer containing no chitosan to obtain another sustained-release composition of the present invention. Further, the same operation was performed without using hyaluronic acid to obtain a sustained-release composition for control.
【００１４】溶出試験を、自動溶出試験システム（富山
産業株式会社）を用い、第十二改正日本薬局方・溶出試
験第２法（パドル法）に準拠して行った。パドル回転数
は１５０rpmに固定し、溶出液としてリン酸緩衝液（ｐ
Ｈ６.８）５００mlを用いて３７℃において行った。溶
出したフェニトインはＨＰＬＣによって定量した。結果
は、図１および図２に示すとおりであった。The dissolution test was carried out using an automatic dissolution test system (Toyama Sangyo Co., Ltd.) according to the twelfth revised Japanese Pharmacopoeia, Dissolution Test Method 2 (paddle method). The paddle rotation speed was fixed at 150 rpm, and phosphate buffer (p
H6.8) was carried out at 37 ° C. with 500 ml. The eluted phenytoin was quantified by HPLC. The results were as shown in FIGS. 1 and 2.
【００１５】（実施例２）ジクロフェナクナトリウムを
用いた本発明の徐放性組成物 ヒアルロン酸（０.１％）とアルギン酸ナトリウム［Ｎ
ＳＰＨ２］（１％）を含む水溶液２ｍｌに、ジクロフェ
ナクナトリウム２５ｍｇを溶解した。この溶液をノズル
を用いて、０.２Ｍ塩化カルシウム溶液中に滴下した。
室温で２４時間放置した後、脱イオン蒸留水５０ｍｌで
洗浄して、本発明の徐放性組成物を得た。(Example 2) Sustained release composition of the present invention using diclofenac sodium Hyaluronic acid (0.1%) and sodium alginate [N
25 mg of diclofenac sodium was dissolved in 2 ml of an aqueous solution containing SPH2] (1%). This solution was dropped into a 0.2M calcium chloride solution using a nozzle.
After leaving it at room temperature for 24 hours, it was washed with 50 ml of deionized distilled water to obtain a sustained release composition of the present invention.
【００１６】また、アルギン酸ナトリウム［ＮＳＰＨ２
または５００Ｇ］のみを含有しヒアルロン酸を含有しな
い水溶液を用いて同様の操作を行って、対照用徐放性組
成物を得た。Further, sodium alginate [NSPH2
Alternatively, the same operation was performed using an aqueous solution containing only 500 G] and not hyaluronic acid to obtain a sustained-release control composition.
【００１７】溶出試験を、自動溶出試験システム（富山
産業株式会社）を用い、第十二改正日本薬局方・溶出試
験第２法（パドル法）に準拠して行った。パドル回転数
は１５０rpmに固定し、溶出液として生理食塩水（０.９
％塩化ナトリウム水溶液）５００mlを用いて３７℃にお
いて行った。溶出したジクロフェナクナトリウムは２７
５ｎｍにおける吸光度を測定することによって定量し
た。結果は、図３に示すとおりであった。The dissolution test was carried out using an automatic dissolution test system (Toyama Sangyo Co., Ltd.) in accordance with the twelfth revised Japanese Pharmacopoeia, Dissolution Test Method 2 (paddle method). The paddle speed was fixed at 150 rpm, and physiological saline (0.9%) was used as the eluent.
% Sodium chloride aqueous solution) at 37 ° C. 27 of diclofenac sodium eluted
It was quantified by measuring the absorbance at 5 nm. The result was as shown in FIG.
【００１８】（実施例３）ブリリアント・ブルーを用い
た本発明の徐放性組成物 ヒアルロン酸（０.１％）とアルギン酸ナトリウム［２
０Ｍ］（１％）を含む水溶液５mlにブリリアント・ブル
ー（Ｂ.Ｂ）１０mgを溶解した。この溶液をノズルを用
いて０.２Ｍ塩化カルシウム溶液５０ml（ｐＨ７.５）中
に滴下した。３７℃で２４時間放置した後、脱イオン蒸
留水５０mlで１０分ずつ３回洗浄し、本発明の徐放性組
成物を得た。Example 3 Sustained Release Composition of the Present Invention Using Brilliant Blue Hyaluronic acid (0.1%) and sodium alginate [2
10 mg of brilliant blue (BB) was dissolved in 5 ml of an aqueous solution containing 0M] (1%). This solution was added dropwise using a nozzle into 50 ml of 0.2 M calcium chloride solution (pH 7.5). After leaving it at 37 ° C. for 24 hours, it was washed with 50 ml of deionized distilled water 3 times for 10 minutes each to obtain a sustained release composition of the present invention.
【００１９】また、アルギン酸ナトリウム［２０Ｍ］の
みを含有し、ヒアルロン酸を含有しない水溶液を用いて
同様の操作を行い、対照用徐放性組成物を得た。Further, the same operation was carried out using an aqueous solution containing only sodium alginate [20M] but not hyaluronic acid to obtain a sustained-release control composition.
【００２０】溶出試験を、自動溶出試験システム（富山
産業株式会社）を用い、第十二改正日本薬局方・溶出試
験第２法（パドル法）に準拠して行った。パドル回転数
は１５０rpmに固定し、溶出液として生理食塩水（０.９
％塩化ナトリウム水溶液）５００mlを用いて３７℃にお
いて行った。溶出したブリリアント・ブルーは５９０nm
における吸光度を測定することによって定量した。結果
は図４に示すとおりであった。The dissolution test was carried out by using an automatic dissolution test system (Toyama Sangyo Co., Ltd.) in accordance with the twelfth revised Japanese Pharmacopoeia, Dissolution Test Method 2 (paddle method). The paddle speed was fixed at 150 rpm, and physiological saline (0.9%) was used as the eluent.
% Sodium chloride aqueous solution) at 37 ° C. Brilliant blue eluted at 590 nm
It was quantified by measuring the absorbance at. The result was as shown in FIG.
【００２１】[0021]
【発明の効果】本発明の徐放性組成物は、その成分であ
るアルギン塩の種類やヒアルロン酸の使用量などを適宜
選択することによって放出パターンを所望の形にするこ
とができる。したがって、本発明の徐放性組成物の応用
範囲は極めて広汎にわたるものと期待される。INDUSTRIAL APPLICABILITY The sustained-release composition of the present invention can have a desired release pattern by appropriately selecting the type of algin salt, the amount of hyaluronic acid used, and the like as its components. Therefore, the application range of the sustained-release composition of the present invention is expected to be extremely wide.
【図１】キトサンを含有しない徐放性組成物について、
ヒアルロン酸含有量の多少によるフェニトイン放出パタ
ーンの変化を示した図である。FIG. 1 shows a sustained release composition containing no chitosan.
It is a figure which showed the change of the phenytoin release pattern with the amount of hyaluronic acid content.
【図２】キトサンを含有する徐放性組成物について、ヒ
アルロン酸含有量の多少によるフェニトイン放出パター
ンの変化を示した図である。FIG. 2 is a diagram showing changes in the phenytoin release pattern depending on the amount of hyaluronic acid contained in a sustained release composition containing chitosan.
【図３】徐放性組成物にヒアルロン酸を含有させること
によるジクロフェナクナトリウム放出パターンの変化を
示した図である。FIG. 3 is a diagram showing changes in the diclofenac sodium release pattern due to the inclusion of hyaluronic acid in the sustained release composition.
【図４】徐放性組成物にヒアルロン酸を含有させること
によるブリリアント・ブルーの放出パターンの変化を示
した図である。FIG. 4 is a diagram showing changes in the release pattern of brilliant blue when the sustained release composition contains hyaluronic acid.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 川田 秀美 埼玉県所沢市北所沢町1992−17 ウイング コート所沢 Ｐ１−202 (72)発明者 治田 豊 東京都東村山市栄町１−４−６ ハイツ久 米川404 (72)発明者 河島 進 石川県金沢市笠舞１−19−１ (72)発明者 宮本 悦子 石川県能美郡辰口町字緑ヶ丘10−21 (72)発明者 村田 慶史 石川県金沢市緑ヶ丘21−47 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Hidemi Kawada, 1992-17 Kitakorozawa-machi, Tokorozawa, Saitama Prefecture Wing Court Tokorozawa P1-202 (72) Inventor, Yutaka Jita 1-4-6, Sakaemachi, Higashimurayama-shi, Tokyo Heights Hisome 404 (72) Inventor Susumu Kawashima 1-19-1 Kasamai, Kanazawa, Ishikawa Prefecture (72) Inventor Etsuko Miyamoto 10-21, Midorigaoka, Tatsunokuchi-cho, Nomi-gun, Ishikawa Prefecture (21) Keiji Murata 21 Midorigaoka, Kanazawa-shi, Ishikawa Prefecture 47
Claims (1)
ルロン酸からなる徐放性組成物。1. A sustained-release composition comprising a content to be released, alginic acid and hyaluronic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25627392A JPH06100468A (en) | 1992-09-25 | 1992-09-25 | Sustained release composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25627392A JPH06100468A (en) | 1992-09-25 | 1992-09-25 | Sustained release composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06100468A true JPH06100468A (en) | 1994-04-12 |
Family
ID=17290359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25627392A Pending JPH06100468A (en) | 1992-09-25 | 1992-09-25 | Sustained release composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06100468A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| JPH11130697A (en) * | 1997-10-27 | 1999-05-18 | Ss Pharmaceut Co Ltd | Pharmaceutical composition with controlled drug release rate |
| US6242488B1 (en) | 1997-08-20 | 2001-06-05 | University Of Oklahoma | Method for preventing and treating pain |
| WO2005058068A1 (en) * | 2003-12-17 | 2005-06-30 | Novozymes Biopolymer A/S | Method for preparing a food product comprising texturizers |
| JP2008173615A (en) * | 2007-01-22 | 2008-07-31 | Ehime Prefecture | Manufacturing method of functional material, functional material, sheet-like structure, and sanitary product |
| JP2014076971A (en) * | 2012-10-11 | 2014-05-01 | Pola Chem Ind Inc | Method of producing nano particles including chitosan and hyaluronan |
| JP2014114272A (en) * | 2012-10-11 | 2014-06-26 | Pola Chem Ind Inc | Nanoparticle including chitosan and hyaluronan |
| US9656001B2 (en) | 2010-10-08 | 2017-05-23 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US9896561B2 (en) | 2008-02-26 | 2018-02-20 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US10279042B2 (en) | 2010-10-08 | 2019-05-07 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| US11980700B2 (en) | 2017-03-08 | 2024-05-14 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
| US12453804B2 (en) | 2012-12-11 | 2025-10-28 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
-
1992
- 1992-09-25 JP JP25627392A patent/JPH06100468A/en active Pending
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242488B1 (en) | 1997-08-20 | 2001-06-05 | University Of Oklahoma | Method for preventing and treating pain |
| US6426368B2 (en) | 1997-08-20 | 2002-07-30 | Warner-Lambert Company | Method for preventing and treating alcoholism |
| US6942876B2 (en) | 1997-09-08 | 2005-09-13 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6593368B2 (en) | 1997-09-08 | 2003-07-15 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| JPH11130697A (en) * | 1997-10-27 | 1999-05-18 | Ss Pharmaceut Co Ltd | Pharmaceutical composition with controlled drug release rate |
| WO2005058068A1 (en) * | 2003-12-17 | 2005-06-30 | Novozymes Biopolymer A/S | Method for preparing a food product comprising texturizers |
| JP2008173615A (en) * | 2007-01-22 | 2008-07-31 | Ehime Prefecture | Manufacturing method of functional material, functional material, sheet-like structure, and sanitary product |
| US10442911B2 (en) | 2008-02-26 | 2019-10-15 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US12031008B2 (en) | 2008-02-26 | 2024-07-09 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US11760858B2 (en) | 2008-02-26 | 2023-09-19 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US10982068B2 (en) | 2008-02-26 | 2021-04-20 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US9896561B2 (en) | 2008-02-26 | 2018-02-20 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| US10279042B2 (en) | 2010-10-08 | 2019-05-07 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
| US11857701B2 (en) | 2010-10-08 | 2024-01-02 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US9656001B2 (en) | 2010-10-08 | 2017-05-23 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US11058802B2 (en) | 2010-10-08 | 2021-07-13 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US11246937B2 (en) | 2010-10-08 | 2022-02-15 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
| US11890344B2 (en) | 2010-10-08 | 2024-02-06 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
| US11744926B2 (en) | 2010-10-08 | 2023-09-05 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US10314950B2 (en) | 2010-10-08 | 2019-06-11 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| JP2014114272A (en) * | 2012-10-11 | 2014-06-26 | Pola Chem Ind Inc | Nanoparticle including chitosan and hyaluronan |
| JP2014076971A (en) * | 2012-10-11 | 2014-05-01 | Pola Chem Ind Inc | Method of producing nano particles including chitosan and hyaluronan |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| US12453804B2 (en) | 2012-12-11 | 2025-10-28 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| US11980700B2 (en) | 2017-03-08 | 2024-05-14 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
| US12390559B2 (en) | 2017-03-08 | 2025-08-19 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2657057B2 (en) | Sustained-release drug consisting of double-walled pharmaceutical microcapsules | |
| US6036978A (en) | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease | |
| US3492397A (en) | Sustained release dosage in the pellet form and process thereof | |
| JPH06100468A (en) | Sustained release composition | |
| Boni et al. | Gellan gum microspheres crosslinked with trivalent ion: Effect of polymer and crosslinker concentrations on drug release and mucoadhesive properties | |
| Jain et al. | Alginate drug delivery systems: application in context of pharmaceutical and biomedical research | |
| Shilpa et al. | Controlled delivery of drugs from alginate matrix | |
| Oliveira et al. | Chitosan–pectin multiparticulate systems associated with enteric polymers for colonic drug delivery | |
| JP4234803B2 (en) | Pharmaceutical composition with controlled drug release rate | |
| US7485294B2 (en) | Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof | |
| PT88664B (en) | PROCESS FOR THE PREPARATION OF NEW PREPARATIONS CONTROLLED DELIBERATION OF TETRACYCIN COMPOUNDS | |
| Dupuis et al. | Colonic drug delivery: influence of cross-linking agent on pectin beads properties and role of the shell capsule type | |
| US4873092A (en) | Slow-releasing preparation | |
| WO1991007949A1 (en) | Delayed release formulations | |
| LV12399B (en) | Improved pulsatile once-a-day delivery systems for minocycline | |
| Almurisi et al. | Formulation development of paracetamol instant jelly for pediatric use | |
| JPS63107917A (en) | Ibuprofen slow release medicine and manufacture | |
| del Olmo et al. | Sustained drug release from biopolymer-based hydrogels and hydrogel coatings | |
| EP1079810B1 (en) | Orally administrable compositions comprising cation cross-linked polysaccharide and a polymer digestible in the lower gastrointestinal tract | |
| Reynaud et al. | Pectin beads loaded with chitosan–iron microspheres for specific colonic adsorption of ciprofloxacin | |
| JP3207587B2 (en) | Sustained release composition | |
| JPH0436233A (en) | Sustained release preparation containing physiologically active substance and decomposable and absorbable in living body | |
| JP2511612B2 (en) | Sustained release composition | |
| Cekić et al. | Influence of the preparation procedure and chitosan type on physicochemical properties and release behavior of alginate–chitosan microparticles | |
| JPH0688901B2 (en) | Liquid long-term release pharmaceutical composition containing ionic drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20010515 |